U.S. Food and Drug Administration Approves CSL's Hemgenix(R) eEtranacogene dezaparvovec-drlb), the First Gene Therapy for Hemophilia B
This historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX levels for years after a one-time infusion
With the app... Biopharmaceuticals, FDA CSL, HEMGENIX, etranacogene dezaparvovec-drlb, hemophilia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Food and Drug Administration (FDA) | Gene Therapy | Genetics | Haemophilia | Hemophilia | Pharmaceuticals